Stay updated on Pembrolizumab+Lenvatinib vs Chemo in Endometrial Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Lenvatinib vs Chemo in Endometrial Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab+Lenvatinib vs Chemo in Endometrial Carcinoma Clinical Trial page
- Check7 days agoChange DetectedFooter Revision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedRevision: v3.5.0 was added and Revision: v3.4.3 was removed from the record history.SummaryDifference0.0%

- Check43 days agoChange DetectedA new revision entry v3.4.3 was added to the history, and the previous v3.4.2 entry was removed.SummaryDifference0.0%

- Check71 days agoChange DetectedAdded Revision: v3.4.2 to the history. Removed notices about government funding lapse and NIH Clinical Center operating status (Revision: v3.4.1).SummaryDifference0.3%

- Check78 days agoChange DetectedA new revision (v3.4.1) was added, introducing core study sections such as Adverse Events, Outcome Measures, Baseline Characteristics, Participant Flow, Eligibility, Arms and Interventions, Study Status, and Study Identification, replacing the previous revision (v3.4.0).SummaryDifference0.7%

- Check85 days agoChange DetectedUI and metadata changes include a new 'Show glossary' option and color-coded highlights for additions and deletions, with the footer updated to Revision: v3.4.0 and the prior v3.3.4 entry removed.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab+Lenvatinib vs Chemo in Endometrial Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Lenvatinib vs Chemo in Endometrial Carcinoma Clinical Trial page.